The significant residual risk of macrovascular events and microvascular complications which persists in most patients despite current standards of care, including achievement of low-density lipoprotein cholesterol (LDL-C) goal and intensive control of blood pressure and blood glucose.

Although statin therapy is the cornerstone of dyslipidemia management, LDL-C lowering with statins reduces major coronary events by approximately one quarter, with 75% of events still occurring.

Multifactorial intensive therapies (including statins) are insufficient to prevent the development or progression of microvascular disease (retinopathy, nephropathy, neuropathy) in up to 50% of patients with the common form of diabetes (known as type 2 diabetes or T2D).